<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00707590</url>
  </required_header>
  <id_info>
    <org_study_id>MB116-001</org_study_id>
    <nct_id>NCT00707590</nct_id>
  </id_info>
  <brief_title>Safety Study to Evaluate BMS-767778 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus (T2DM)</brief_title>
  <official_title>Randomized, Double-Blind, Placebo-Controlled Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-767778 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety and tolerability and the PK/PD relationship of BMS-767778 administered&#xD;
      as single and multiple oral doses in healthy subjects, and in subjects with T2DM&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AEs, vital signs, ECG and clinical laboratory test results</measure>
    <time_frame>throughout the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Single and multiple dose (14 days) PK</measure>
    <time_frame>throughout the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DPP-4 inhibition and incretin response</measure>
    <time_frame>throughout the study</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A: BMS-767778, Oral Solution, Oral, 1 mg, once daily, 1 day OR Placebo Comparator, Oral Solution, Oral, 0 mg, once daily, 1 day&#xD;
B: BMS-767778, Oral Solution, Oral, 3 mg, once daily, 1 day OR Placebo Comparator, Oral Solution, Oral, 0 mg, once daily, 1 day&#xD;
C: BMS-767778, Capsules, Oral, 10 mg, once daily, 1 day OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 1 day&#xD;
D: BMS-767778, Capsules, Oral, 30 mg, once daily, 1 day OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 1 day&#xD;
E: BMS-767778, Capsules, Oral, 100 mg, once daily, 1 day OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 1 day&#xD;
F: BMS-767778, Capsules, Oral, 300 mg, once daily, 2 days OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 2 days&#xD;
G: BMS-767778, Capsules, Oral, 600 mg, once daily, 1 day OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 1 day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A: BMS-767778, Capsules, Oral, 10 mg, once daily, 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 14 days&#xD;
B: BMS-767778, Capsules, Oral, 30 mg, once daily, 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 14 days&#xD;
C: BMS-767778, Capsules, Oral, 100 mg, once daily, 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 14 days&#xD;
D: BMS-767778, Capsules, Oral, 300 mg, once daily, 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 14 days&#xD;
E: BMS-767778, Capsules, Oral, 600 mg, once daily, 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A: BMS-767778, Capsules, Oral, Adaptive design (between 10 to 600 mg), 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, 14 days&#xD;
B: BMS-767778, Capsules, Oral, Adaptive design (between 10 to 600 mg), 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-767778 or Placebo</intervention_name>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_label>Part B</arm_group_label>
    <arm_group_label>Part C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Parts A and Part B of the study (maximum age 45 years):&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male and female subjects as determined by medical history, physical&#xD;
             examination, 12-lead electrocardiogram (ECG), and clinical laboratory evaluations will&#xD;
             be eligible to participate in the study.&#xD;
&#xD;
          -  Men and women who are not of childbearing potential (i.e., who are postmenopausal or&#xD;
             surgically sterile)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of organ dysfunction or any clinically significant deviation from normal in&#xD;
             physical examination, vital signs, ECG or clinical laboratory determinations&#xD;
&#xD;
        Part C of the study (maximum age 65 years):&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Drug naive patients with T2DM or patients who are on metformin-monotherapy (at current&#xD;
             dose for â‰¥ 8 weeks) with inadequately controlled blood glucose levels (HbA1c &gt;7 %and&#xD;
             &lt;10 %) Men and women who are not of childbearing potential (i.e., who are&#xD;
             postmenopausal or surgically sterile)&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Poorly controlled diabetes with either new onset or worsening of symptoms of polyuria&#xD;
             and polydipsia, weight loss, fatigue, abdominal pain, or other significant signs and&#xD;
             symptoms&#xD;
&#xD;
          -  Any of the following medical conditions: uncontrolled hypertension, unstable angina&#xD;
             pectora, Cushing's syndrome, Addison's disease, uncontrolled hyperthyroidism or&#xD;
             hypothyroidism, significant liver disease or renal failure, malignant diseases, or&#xD;
             immunodeficiency (e.g., HIV/AIDS or organ-transplant), or history of myocardial&#xD;
             infarction, congestive heart failure defined as New York Heart Association (NYHA)&#xD;
             stage II and above, significant valvular disease, cardiac arrhythmia, or transient&#xD;
             ischemic attack or cerebrovascular accidents (occurred within 6 months prior to entry&#xD;
             into the study), or family history of Long QT Syndrome&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Quebec</city>
        <zip>G1P 0A2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <study_first_submitted>June 27, 2008</study_first_submitted>
  <study_first_submitted_qc>June 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2008</study_first_posted>
  <last_update_submitted>February 9, 2009</last_update_submitted>
  <last_update_submitted_qc>February 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2009</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>Bristol-Myers Squibb</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

